Wang Dong, Luo Liang, Chen Wei, Chen Lian-Zhou, Zeng Wen-Tao, Li Wen, Huang Xiao-Hui
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, P.R. China.
Department of Medical Intensive Care Unit, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, P.R. China.
Oncol Rep. 2014 Mar;31(3):1199-204. doi: 10.3892/or.2013.2946. Epub 2013 Dec 23.
The aim of the present study was to investigate the expression of vascular endothelial growth factor (VEGF) and macrophage migration inhibitory factor (MIF) in HCC progression and their correlation with clinicopathological factors as well as the relationship between their expression levels. The expression of serum VEGF and MIF was evaluated in 150 patients with HCC and in 30 normal volunteers by enzyme-linked immunosorbent assay (ELISA). VEGF and MIF expression levels were evaluated by immunohistochemistry on tissue microarrays containing 150 HCCs with paired adjacent non-cancer liver tissues. VEGF and MIF mRNA levels were determined by quantitative PCR in another 48 HCCs. The correlation of VEGF and MIF with clinicopathological factors was analyzed in HCC. Serum VEGF and MIF concentrations were higher in HCC patients than the levels in the controls. The expression levels of VEGF and MIF in the HCC tissues were both higher than those in the adjacent non-tumor liver tissues. Overexpression of VEGF and MIF was significantly associated with tumor size (P=0.027 and 0.022, respectively), intrahepatic metastasis (P=0.032 and 0.027, respectively), vascular invasion (P=0.044 and 0.039, respectively) and TNM stage (P=0.028 and 0.013, respectively). Furthermore, VEGF and MIF mRNA levels were higher in HCC compared to levels in the paired non-cancer liver tissues. VEGF and MIF mRNA levels were correlated with tumor stage and metastasis. The expression of VEGF was positively related with MIF expression in HCC. The expression of MIF and VEGF in HCC was markedly positively correlated, which suggests that MIF and VEGF play an important role in the progression of HCC. Both factors may concomitantly accelerate the progression of HCC.
本研究的目的是探讨血管内皮生长因子（VEGF）和巨噬细胞移动抑制因子（MIF）在肝癌进展中的表达及其与临床病理因素的相关性，以及它们表达水平之间的关系。采用酶联免疫吸附测定（ELISA）法检测150例肝癌患者和30名正常志愿者血清VEGF和MIF的表达。通过免疫组织化学法检测包含150例肝癌及配对癌旁非癌肝组织的组织芯片中VEGF和MIF的表达水平。采用定量PCR法检测另外48例肝癌中VEGF和MIF的mRNA水平。分析肝癌中VEGF和MIF与临床病理因素的相关性。肝癌患者血清VEGF和MIF浓度高于对照组。肝癌组织中VEGF和MIF的表达水平均高于癌旁非肿瘤肝组织。VEGF和MIF的过表达与肿瘤大小（分别为P=0.027和0.022）、肝内转移（分别为P=0.032和0.027）、血管侵犯（分别为P=0.044和0.039）及TNM分期（分别为P=0.028和0.013）显著相关。此外，与配对的非癌肝组织相比，肝癌中VEGF和MIF的mRNA水平更高。VEGF和MIF的mRNA水平与肿瘤分期和转移相关。肝癌中VEGF的表达与MIF的表达呈正相关。肝癌中MIF和VEGF的表达显著正相关，这表明MIF和VEGF在肝癌进展中起重要作用。这两种因子可能共同加速肝癌的进展。
